8.37 USD
▼-0.37-4.23%
盘后 8.86 0.00%
2026-09-15
市值
$935.00M
市盈率
—
EPS
-1.87
股息率
—
52 周区间
3.79 – 11.45
成交量
1.51M
Beta
2.44
目标价
18.67
52W 低 3.7952W 高 11.45
价格走势
公司简介
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat...